A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma

Abstract

Peer reviewed

Joseph Clark, Marc S. Ernstoff, Mohammed M. Milhem, Christopher D. Lao, David H. Lawson, Lawrence E. Flaherty, Theresa L. Luna and Sandra Aung

Journal of clinical oncology, Vol.33(15_suppl), pp.9053-9053

05/20/2015

DOI: 10.1200/jco.2015.33.15_suppl.9053

View Online

Title: Subtitle: A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma
Creators: Joseph Clark - Loyola University Medical Center
Marc S. Ernstoff - Dartmouth–Hitchcock Medical Center
Mohammed M. Milhem - University of Iowa
Christopher D. Lao - University of Michigan–Ann Arbor
David H. Lawson - Emory University
Lawrence E. Flaherty - Wayne State University
Theresa L. Luna - Prometheus Research
Sandra Aung - Prometheus
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.33(15_suppl), pp.9053-9053
DOI: 10.1200/jco.2015.33.15_suppl.9053
ISSN: 0732-183X
eISSN: 1527-7755
Language: English
Date published: 05/20/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984363175902771

3 Record Views